4 Mistakes You Must Avoid When Outsourcing Vial Fill-Finish

Advances in large molecule therapeutics have led to exciting growth in the biopharmaceutical market. However, they have also increased the demand for aseptic fill-finish, which requires specialized expertise and capabilities to execute. Biotech and pharma companies without the available capacity to perform these activities in-house will need to work with a qualified CDMO for fill-finish support. Fill-finish is a critical step in your path to the clinic, and any errors at this stage could delay clinical trials or even prevent meeting funding milestones. Be sure to avoid these four common pitfalls when outsourcing your fill-finish project.